Develops treatments for neurological disorders and rare diseases using its proprietary genetics platform.
Xenon Pharmaceuticals Inc., a pioneering biopharmaceutical company based in Burnaby, Canada, focuses on advancing therapies for patients with neurological disorders. Our clinical-stage pipeline is robust, featuring innovative candidates such as XEN496 and XEN1101. XEN496, a Kv7 potassium channel opener, is currently in Phase III clinical trials for KCNQ2 developmental and epilepsy encephalopathy, while XEN1101, also a Kv7 potassium channel opener, is progressing through Phase II trials for epilepsy and other neurological conditions.
In addition to these promising candidates, Xenon Pharmaceuticals is developing NBI-921352, a selective Nav1.6 sodium channel inhibitor, in Phase II trials for SCN8A developmental and epileptic encephalopathy, alongside potential indications like adult focal epilepsy. Further enriching our pipeline is XEN007, a central nervous system-acting calcium channel modulator currently in Phase II clinical trials. We have established strategic collaborations, including a partnership with Neurocrine Biosciences, Inc. to develop treatments for epilepsy and with Flexion Therapeutics, Inc. for the advancement of PCRX301 (XEN402), a Nav1.7 inhibitor targeting post-operative pain.
Founded in 1996, Xenon Pharmaceuticals continues to drive innovation in biopharmaceuticals with a strong commitment to neurological therapeutics. Headquartered in Burnaby, Canada, our company is dedicated to advancing novel treatments that address significant unmet medical needs, aiming to improve the lives of patients worldwide.